New drug combination passes safety test in pancreatic cancer
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study has shown a novel peptide antagonist, given in combination with a PD-1 inhibitor, to be safe and well-tolerated in patients with advanced, refractory pancreatic and rectal cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Genetics | Pancreas | Pancreatic Cancer | Rectal Cancers | Study